AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2838318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31485804 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine hydrochloride (BHCl) 4500 mg
Number of subjects: 9
Study 31485804 — intervention group
Group type: COMPARATOR
Intervention: No acid supplementation
Number of subjects: 9
Study 29248014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) - SC PMTCT plus 'Protect Your Family' intervention; 6 CHCs; n=342
Number of subjects: 699
Study 29248014 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC) - standard care condition plus time-equivalent attention-control; 6 CHCs; n=357
Number of subjects: 699
Study 29248014 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI)
Number of subjects: 699
Study 29248014 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 699
Study 26056249 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 0
Study 26056249 — intervention group
Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 0
Study 26056249 — intervention group
Group type: COMPARATOR
Intervention: Femoral access
Number of subjects: 0
Study 23801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab (14-day full-dose)
Number of subjects: 516
Study 23801579 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 516
Study 23801579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 516
Study 21597220 — intervention group
Group type: EXPERIMENTAL
Intervention: G1: HF 9.6%+Silane+Panavia F2.0
Number of subjects: 32
Study 21597220 — intervention group
Group type: EXPERIMENTAL
Intervention: G2: HF 9.6%+Silane+HT+Panavia F2.0
Number of subjects: 32
Study 21597220 — intervention group
Group type: COMPARATOR
Intervention: G3: Silane+HT+Panavia F2.0
Number of subjects: 32
Study 21597220 — intervention group
Group type: COMPARATOR
Intervention: G4: Silane+Panavia F2.0
Number of subjects: 32
Study 19336502 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg) added to aspirin
Number of subjects: 7554
Study 19336502 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to aspirin
Number of subjects: 7554
Study 16955299 — intervention group
Group type: EXPERIMENTAL
Intervention: Active and passive extension immediately after ACL reconstruction (Group A, n=11)
Number of subjects: 22
Study 16955299 — intervention group
Group type: COMPARATOR
Intervention: No active and passive extension immediately after ACL reconstruction (Group B, n=11)
Number of subjects: 22
Study 16955299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 22
Study 15330214 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM (bleomycin, vincristine, methotrexate)
Number of subjects: 80
Study 15330214 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM and mitolactol (dibromodulcitol)
Number of subjects: 80
Study 15330214 — intervention group
Group type: EXPERIMENTAL
Intervention: BVM and cisplatin
Number of subjects: 80
Study 15330214 — intervention group
Group type: COMPARATOR
Intervention: BVM alone (Group N)
Number of subjects: 80
Study 10873076 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene 40 mg/day for 14-21 days
Number of subjects: 77
Study 10873076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10873076 — intervention group
Group type: EXPERIMENTAL
Intervention: Idoxifene
Number of subjects: 77
Study 9296417 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural anesthesia (CSEA)
Number of subjects: 120
Study 9296417 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia (EA)
Number of subjects: 120
Study 8296487 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin treatment (6 subjects)
Number of subjects: 13
Study 8296487 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 subjects, untreated)
Number of subjects: 13
Study 3113973 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg X kg‐1 once daily for 3 days
Number of subjects: 46
Study 3113973 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg X kg‐1 thrice daily for one day
Number of subjects: 46
Study 3113973 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg X kg‐1 thrice daily for one day
Number of subjects: 46
Study 29445116 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D heads-up microscope (3DM) during 25-gauge pars plana vitrectomy (PPV)
Number of subjects: 50
Study 29445116 — intervention group
Group type: COMPARATOR
Intervention: Traditional ophthalmic microscope (TM) during 25-gauge pars plana vitrectomy (PPV)
Number of subjects: 50
Study 26295565 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional PPD antigen
Number of subjects: 69
Study 26295565 — intervention group
Group type: COMPARATOR
Intervention: Intralesional saline (placebo)
Number of subjects: 69
Study 26295565 — intervention group
Group type: COMPARATOR
Intervention: Cryotherapy
Number of subjects: 69
Study 23820295 — intervention group
Group type: EXPERIMENTAL
Intervention: Walkaround (body postural support)
Number of subjects: 22
Study 23820295 — intervention group
Group type: COMPARATOR
Intervention: Control (conventional means: cane, therapist)
Number of subjects: 22
Study 22690198 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition educational program delivered by trained classroom teachers
Number of subjects: 464
Study 20868279 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-dose nevirapine (FD)
Number of subjects: 211
Study 20868279 — intervention group
Group type: COMPARATOR
Intervention: Dose escalation (DE) nevirapine
Number of subjects: 211
Study 18778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 320/9 microg
Number of subjects: 1704
Study 18778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI 160/9 microg
Number of subjects: 1704
Study 18778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol pMDI (both dosages)
Number of subjects: 1704
Study 18778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 320/9 microg
Number of subjects: 1704
Study 18778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/9 microg
Number of subjects: 1704
Study 18778120 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 1704
Study 17119047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered intervention consisting of cognitive behavioral therapy and medications
Number of subjects: 0
Study 17119047 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 17119047 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-administered intervention and Usual care
Number of subjects: 0
Study 14624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcysteine 600 mg b.i.d. (five doses)
Number of subjects: 43
Study 14624421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative baseline myoglobin assay
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive baseline myoglobin assay
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete ST resolution (>/=70%)
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial ST resolution (30% to <70%)
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: No ST resolution (<30%)
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative myoglobin assay and complete ST resolution
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive myoglobin assay or ST resolution <70%
Number of subjects: 2079
Study 10966533 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive myoglobin assay and ST resolution <70%
Number of subjects: 2079
Study 8858434 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory information (procedural, sensory, and coping information) plus written information
Number of subjects: 82
Study 8858434 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine advice and support from ward, medical and nursing staff)
Number of subjects: 82
Study 7699420 — intervention group
Group type: EXPERIMENTAL
Intervention: 'eight‐drugs‐in‐one‐day' chemotherapy regimen
Number of subjects: 130
Study 2954253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (1200 mg daily)
Number of subjects: 562
Study 2954253 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg daily)
Number of subjects: 562
Study 2954253 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg)
Number of subjects: 562
Study 2954253 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (1000 mg)
Number of subjects: 562
Study 29282574 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 79
Study 29282574 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 79
Study 29282574 — intervention group
Group type: EXPERIMENTAL
Intervention: Both surgical techniques
Number of subjects: 79
Study 27697758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg) plus dihydroartemisinin-piperaquine (120 mg/960 mg for 36 to <75 kg; 160 mg/1,280 mg for ≥75 to 100 kg)
Number of subjects: 120
Study 27697758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafenoquine (300 mg) plus artemether-lumefantrine (80 mg/480 mg)
Number of subjects: 120
Study 27697758 — intervention group
Group type: COMPARATOR
Intervention: Tafenoquine alone
Number of subjects: 120
Study 27697758 — intervention group
Group type: COMPARATOR
Intervention: Dihydroartemisinin-piperaquine alone
Number of subjects: 120
Study 27697758 — intervention group
Group type: COMPARATOR
Intervention: Artemether-lumefantrine alone
Number of subjects: 120
Study 25640275 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic patient-reported outcomes system
Number of subjects: 104
Study 24241095 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (oral capsule, 3 g/d)
Number of subjects: 100
Study 24241095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21146844 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral feeding (liquid diet on postoperative day 2, soft diet from day 3 until discharge)
Number of subjects: 54
Study 21146844 — intervention group
Group type: COMPARATOR
Intervention: Control group (liquid diet on postoperative day 4)
Number of subjects: 54
Study 18356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meals with barley kernel based bread (ordinary, high‐amylose‐ or beta‐glucan‐rich genotypes)
Number of subjects: 15
Study 18356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meal with white wheat flour bread (WWB) enriched with a mixture of barley fiber and resistant starch
Number of subjects: 15
Study 18356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening meal with barley‐kernel bread
Number of subjects: 15
Study 18356328 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath hydrogen
Number of subjects: 15
Study 16555338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IPC+ group)
Number of subjects: 47
Study 14728106 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 69
Study 14728106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 10881255 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated estrogen (oral Premarin 0.625 mg daily)
Number of subjects: 40
Study 10881255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 7604069 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline effervescent tablet (Euphyllin quick 200)
Number of subjects: 12
Study 2232062 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 13
Study 2232062 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 13
Study 209490 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine (1.0mg)
Number of subjects: 7
Study 209490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31577981 — intervention group
Group type: EXPERIMENTAL
Intervention: Deliberate emotion regulation interpersonal scaffolding
Number of subjects: 60
Study 31577981 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 28555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum subsp. infantis R0033
Number of subjects: 221
Study 28555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium bifidum R0071
Number of subjects: 221
Study 28555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus helveticus R0052
Number of subjects: 221
Study 28555502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 25876740 — intervention group
Group type: EXPERIMENTAL
Intervention: CR+G (genetic test results and counseling)
Number of subjects: 601
Study 25876740 — intervention group
Group type: COMPARATOR
Intervention: CR+EYE (control eye disease counseling)
Number of subjects: 601
Study 23261023 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive strips
Number of subjects: 82
Study 23261023 — intervention group
Group type: COMPARATOR
Intervention: Absorbable sutures (control)
Number of subjects: 82
Study 20473862 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX
Number of subjects: 306
Study 20473862 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX-6
Number of subjects: 306
Study 19657901 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Breathing program
Number of subjects: 10
Study 19657901 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 10
Study 16912619 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg PO betamethasone
Number of subjects: 52
Study 16912619 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg/kg IM dexamethasone
Number of subjects: 52
Study 14993491 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux polysulfone (F 500S)
Number of subjects: 10
Study 14993491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flux polysulfone (F 60S)
Number of subjects: 10
Study 14993491 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-flux cellulose-tri-acetate (Tricea 150G)
Number of subjects: 10
Study 14993491 — intervention group
Group type: COMPARATOR
Intervention: Low-flux polysulfone (PS: F 6HPS)
Number of subjects: 10
Study 11732958 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine TST placement with physician-to-school nurse communication
Number of subjects: 134
Study 11732958 — intervention group
Group type: COMPARATOR
Intervention: Routine TST placement with no physician-to-school nurse communication (Control)
Number of subjects: 134
Study 9142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-nostril breathing
Number of subjects: 130
Study 9142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Left-nostril breathing
Number of subjects: 130
Study 9142556 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-nostril breathing
Number of subjects: 130
Study 9142556 — intervention group
Group type: COMPARATOR
Intervention: Breath awareness
Number of subjects: 130
Study 9142556 — intervention group
Group type: COMPARATOR
Intervention: Practice of mudras
Number of subjects: 130
Study 8070785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amino acids infusion
Number of subjects: 58
Study 8070785 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic amino acids infusion
Number of subjects: 58
Study 8070785 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 58
Study 2853749 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 16
Study 2853749 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 16
Study 2853749 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 31592728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) plus anticoagulation
Number of subjects: 692
Study 31592728 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with anticoagulation alone
Number of subjects: 692
Study 31592728 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacomechanical catheter-directed thrombolysis (PCDT) for iliofemoral DVT
Number of subjects: 692
Study 31592728 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for femoral-popliteal DVT
Number of subjects: 692
Study 28624307 — intervention group
Group type: COMPARATOR
Intervention: Hexavac
Number of subjects: 751
Study 28624307 — intervention group
Group type: COMPARATOR
Intervention: Infanrix hexa
Number of subjects: 751
Study 28624307 — intervention group
Group type: EXPERIMENTAL
Intervention: HBVaxPro challenge dose
Number of subjects: 751
Study 26241077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation (6 ml/kg predicted body weight)
Number of subjects: 128
Study 26241077 — intervention group
Group type: COMPARATOR
Intervention: Usual care ventilation (10 ml/kg)
Number of subjects: 128
Study 26241077 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-tidal volume ventilation
Number of subjects: 128
Study 26241077 — intervention group
Group type: COMPARATOR
Intervention: Usual care ventilation
Number of subjects: 128
Study 24050942 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental medications
Number of subjects: 0
Study 24050942 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up visits
Number of subjects: 0
Study 24050942 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence
Number of subjects: 0
Study 24050942 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses
Number of subjects: 0
Study 24050942 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with adherence
Number of subjects: 0
Study 21144559 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125+
Number of subjects: 39105
Study 21144559 — intervention group
Group type: EXPERIMENTAL
Intervention: TVU+
Number of subjects: 39105
Study 21144559 — intervention group
Group type: EXPERIMENTAL
Intervention: CA-125+/TVU+
Number of subjects: 39105
Study 19803539 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel 100 mg/m2 IV infusion every 21 days
Number of subjects: 0
Study 19803539 — intervention group
Group type: COMPARATOR
Intervention: Pac3w (Paclitaxel 175 mg/m2 IV infusion every 21 days)
Number of subjects: 0
Study 19803539 — intervention group
Group type: COMPARATOR
Intervention: Pac1w (Paclitaxel administered in 1-week cycles)
Number of subjects: 0
Study 19803539 — intervention group
Group type: COMPARATOR
Intervention: Nab-P (nano albumin-bound paclitaxel given every 3 weeks)
Number of subjects: 0
Study 16856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing within 2 consecutive days (FRP)
Number of subjects: 71
Study 16856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Three one‐stage, full‐mouth disinfection protocols (FM) applying antiseptics
Number of subjects: 71
Study 16856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine for 2 months (FMCHX)
Number of subjects: 71
Study 16856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride for 2 months (FMF)
Number of subjects: 71
Study 16856902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine for 2 months followed by amine fluoride/stannous fluoride for another 6 months (FMCHX+F)
Number of subjects: 71
Study 16856902 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing, quadrant by quadrant, at two‐week intervals (negative control, NC)
Number of subjects: 71
Study 12904192 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine-ropivacaine (PR)
Number of subjects: 40
Study 12904192 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-ropivacaine (SR)
Number of subjects: 40
Study 12904192 — intervention group
Group type: COMPARATOR
Intervention: Saline-saline (SS)
Number of subjects: 40
Study 10981242 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2 g every eight hours
Number of subjects: 276
Study 10981242 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2 g every eight hours
Number of subjects: 276
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rb expression
Number of subjects: 105
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rb and E‐cadherin expression
Number of subjects: 105
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rb and myc expression
Number of subjects: 105
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of eosinophilic and lymphocytic infiltrates
Number of subjects: 105
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of lymphocytic infiltrate
Number of subjects: 105
Study 8956793 — intervention group
Group type: EXPERIMENTAL
Intervention: TNM stage (I + II) and marked lymphocytic infiltrate
Number of subjects: 105
Study 1526693 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilidine-naloxone
Number of subjects: 50
Study 1526693 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine
Number of subjects: 50
Study 6419574 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sustained-release nitroglycerin (SRNG, 6.5 mg)
Number of subjects: 46
Study 30615058 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher triglycerides (TG) ≥150 mg/dl
Number of subjects: 12549
Study 30615058 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher TG:HDL-C ratio ≥2.7
Number of subjects: 12549
Study 30615058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower total cholesterol (TC) ≥200 mg/dl
Number of subjects: 12549
Study 30615058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower low-density lipoprotein cholesterol (LDL-C) ≥130 mg/dl
Number of subjects: 12549
Study 29373094 — intervention group
Group type: EXPERIMENTAL
Intervention: SB3 (trastuzumab biosimilar)
Number of subjects: 800
Study 29373094 — intervention group
Group type: COMPARATOR
Intervention: TRZ (reference trastuzumab)
Number of subjects: 800
Study 27179795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined strength and speed endurance training (CSS; n = 9)
Number of subjects: 16
Study 27179795 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 7)
Number of subjects: 16